35.01

2.11% 0.7194

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $35.01, with a volume of 67,252. It is up +2.11% in the last 24 hours and down -2.33% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$34.29

Open:

$34.35

24h Volume:

67,252

Relative Volume:

0.10

Market Cap:

$2.06B

Revenue:

$681.88M

Net Income/Loss:

$122.63M

P/E Ratio:

16.59

EPS:

2.11

Net Cash Flow:

$220.18M

1W Performance:

+8.88%

1M Performance:

-2.33%

6M Performance:

+3.41%

1Y Performance:

+4.46%

1-Day Range:

$34.08

$35.05

1-Week Range:

$32.08

$35.05

52-Week Range:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1166)

Industry

Biotechnology (652)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

268

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	35.05	2.06B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	483.00	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	563.97	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.96	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	562.04	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	251.68	28.51B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Jun 16, 2025

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement - insights.citeline.com

Jun 16, 2025

Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment - MyChesCo

Jun 16, 2025

Jun 15, 2025

Rhumbline Advisers Increases Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Jun 15, 2025

Jun 14, 2025

Harmony Biosciences to begin human trials of narcolepsy drug in 2025 By Investing.com - Investing.com South Africa

Jun 11, 2025

Harmony Biosciences to begin human trials of narcolepsy drug in 2025 - Investing.com Canada

Jun 11, 2025

HRMY: Harmony Biosciences Shows Promising Preclinical Data for BP1.15205 | HRMY Stock News - GuruFocus

Jun 11, 2025

Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 - StreetInsider

Jun 11, 2025

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 - Business Wire

Jun 11, 2025